Previous HCV Non-Responders Win in Phase III Telaprevir Study
Vertex reports positive results from Phase III hepatitis trial
Sep 09, 2010
Vertex Pharmaceuticals, a biotechnology company, has announced that 65% of people overall achieved a sustained viral response, or SVR/viral cure, with a telaprevir-based regimen in the pivotal Phase III Realize study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.
Realize was a pivotal Phase III, randomized, double-blind, placebo-controlled study conducted in 662 people at more than 100 international clinical trial sites with the majority in Europe and North America.
Continue reading this entire article: